Consolidated Balance Sheets - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 2,400,000	$ 3,513,000
Accounts receivable, net of allowance for doubtful accounts of $419,000 ($274,000 at December 31, 2017)	1,495,000	1,687,000
Accounts receivable – related party	14,000	862,000
Inventories, net of reserves of $258,000 ($1,069,000 at December 31, 2017)	4,493,000	4,798,000
Prepaid expenses and other current assets	224,000	594,000
Total current assets	8,626,000	11,454,000
Restricted cash	1,000,000	1,000,000
Equipment and leasehold improvements, net	2,562,000	2,996,000
Goodwill	781,000	13,976,000
Intangible assets, net	1,591,000	21,629,000
Other assets	51,000	56,000
Total assets	14,611,000	51,111,000
Current liabilities:
Accounts payable	2,423,000	2,079,000
Accrued payroll and related expenses	703,000	532,000
Deferred revenue	485,000	384,000
Related party payable		606,000
Interest payable – related party	1,513,000	657,000
Other current liabilities	1,241,000	1,206,000
Total current liabilities	6,365,000	5,464,000
Convertible promissory note – related party, less debt discount of $6,026,000 ($0 at December 31, 2017)	1,174,000	6,700,000
Derivative obligations	1,000	597,000
Noncurrent deferred tax liability		4,730,000
Other noncurrent liabilities	340,000	408,000
Total liabilities	7,880,000	17,899,000
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value; 2,000,000 shares authorized, none issued and outstanding at December 31, 2018 and 2017
Common stock, $0.001 par value; 350,000,000 shares authorized; 21,649,147 issued and outstanding (10,872,428 at December 31,2017)	22,000	11,000
Paid in capital in excess of par	235,868,000	221,371,000
Accumulated deficit	(227,435,000)	(187,640,000)
Accumulated other comprehensive loss	(13,000)	(43,000)
Total Cesca Therapeutics Inc. stockholders’ equity	8,442,000	33,699,000
Non-controlling interests	(1,711,000)	(487,000)
Total equity	6,731,000	33,212,000
Total liabilities and stockholders’ equity	$ 14,611,000	$ 51,111,000